|
|
||||||||
RESEARCH REPORT |
1 Department of Oral Pathology, Hospital and School of Stomatology, Peking University, 22 South Zhongguancun Avenue, Haidian District, Beijing 100081, PR China; and
2 Center for Human Disease Genomics, Peking University Health Science Center
* corresponding authors, litiejun22{at}vip.sina.com or hongshan{at}bjmu.edu.cn
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: PTCH mutation odontogenic keratocyst Gorlin syndrome
| INTRODUCTION |
|---|
|
|
|---|
It is now believed that Gorlin syndrome is caused by germ-line mutations of the PTCH gene (Hahn et al., 1996; Johnson et al., 1996). In about 6085% of individuals fulfilling the diagnostic criteria of the syndrome, it is possible to identify the underlying PTCH defect (Evans and Farndon, GeneReview at www.genetests.org, 2004). The PTCH gene is the human homologue of the Drosophila segment polarity gene patched and has been localized to chromosome 9q22.3-q31 (GenBank accession numbers: U43148 and U59464; Hahn et al., 1996; Johnson et al., 1996). It encodes a 12-transmembranous-domain protein that physically binds at least 1 of the 3 known vertebrate Hedgehog moleculesSonic hedgehog (SHH)with high affinity, controlling cell fate and embryonic patterning in numerous tissues (Stone et al., 1996; Hardcastle et al., 1998). Apart from the high frequency of germ-line mutations of the PTCH gene detected in patients with the syndrome, somatic mutations of PTCH have also been identified in a range of sporadically occurring tumors, including those observed in the syndrome, i.e., basal cell carcinomas (Gailani et al., 1996; Hahn et al., 1996; Johnson et al., 1996), medulloblastoma (Xie et al., 1997), and trichoepithelioma (Vorechovsky et al., 1997). Similarly, several studies demonstrated the presence of PTCH mutations in syndromic and non-syndromic keratocysts (Lench et al., 1997; Barreto et al., 2000; Ohki et al., 2004). However, the prevalence and range of PTCH mutations in odontogenic keratocysts remain to be established, in view of the limited number of cysts examined to date. The present study aimed to analyze PTCH mutations in a group of Chinese patients presenting with non-syndromic and Gorlin-syndrome-related keratocysts.
| MATERIALS & METHODS |
|---|
|
|
|---|
DNA Extraction and Polymerase Chain-reaction (PCR)
Genomic DNA from frozen samples (25 mg) of cyst tissue was extracted with a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA). DNA from peripheral blood was isolated with a Whole Blood Genomic DNA Mini Kit (V-gene Biotechnology Limited, Hangzhou, P.R. China). Each of the 23 exons of the PTCH gene was amplified separately with specific primers, as previously described (Chidambaram et al., 1996; Hahn et al., 1996; Xie et al., 1997), except for exon 14 and exon 23. Exon 14 was amplified in 2 pieces, 5'-AAAATGGCAGAATGAAAGCACC-3', 5'-CTGAGGGTGTCC TGTGTCAC-3' and 5'-CACACGCACGTGTACTACAC-3', 5'-CTGATGAACTCCAAAGGTTCTG-3'. Exon 23 was also amplified in 2 pieces, 5'-AACCCAAGGAGGGAAGTGTG-3', 5'-AAGCCGTCACAGTGGTGATG-3' and 5'-TCTACTGAAGGG CATTCTGGC-3', 5'-GAACCTTGTCCTCCTCTTTGC-3'. PCRs were performed in a final volume of 50 µL containing approximately 100 ng of template DNA, 200 µM dNTPs, 10 pmol of each primer, 1.25 u of Taq polymerase [TaKaRa Biotechnology (Dalian) Co., Ltd, P.R. China], 50 mM KCl, 10 mM Tris-HCl, and 1.5 mM MgCl2. Amplification was performed for 35 cycles at 94°C for 30 sec, 57°C for 30 sec, and 72°C for 30 sec in a thermal cycler (PTC-100; MJ Research, Watertown, MA, USA).
Direct Sequencing
PCR products were gel-purified with a Gel Extraction kit (Omega Bio-Tek, Doraville, GA, USA) , according to the manufacturers protocol, and directly sequenced with the same primers as for the original PCR amplification. When insertion or deletion of multiple nucleotides occurred, and direct sequencing from the PCR products became difficult, further mutation detection was pursued in a subset of samples by the cloning of purified PCR product into the plasmid vector pGEM-T (Promega, Madison, WI, USA). After transformation into the competent E. coli strain TOP10, colonies carrying recombinant plasmid were selected, and the plasmid DNA was isolated with the use of a Plasmid Miniprep Kit (Sigma, St. Louis, MO, USA). Plasmid DNA was sequenced with M13 universal forward and reverse primers. Sequencing analysis was performed on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Any mutation detected was confirmed by reverse sequencing and by analysis of samples from at least 2 independent PCRs.
| RESULTS |
|---|
|
|
|---|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
In the present study, we have identified 4 novel and 1 known PTCH mutations in 5 cysts, 2 of which were associated with Gorlin syndrome. A known germ-line mutation found in a syndrome patient was a nonsense mutation (2619C>A) resulting in PTCH protein truncation in the second extracellular loop. An identical germ-line mutation has been previously reported in a French Gorlin syndrome patient (Boutet et al., 2003). The second extracellular loop of PTCH is known to be an important domain that interacts with SHH (Gailani et al., 1996). Thus, PTCH protein truncation in this region may inactivate its ability to bind SHH ligand. The novel germ-line mutation (1338_1339insGCG) identified from the other syndrome patient resulted in an insertion of alanine in the second transmembrane domain of the PTCH protein, a region known as the sterol-sensing domain (SSD). Analysis of recent data from Drosophila suggests that the SSD may play a role in mediating intracellular PTCH trafficking as a means of regulating Smoothened (Strutt et al., 2001). Thus, insertion of an amino acid residue in the SSD may disturb signaling transduction in the SHH signaling pathway. We also identified 3 novel somatic mutations in 3 non-syndromic keratocysts. One deletion mutation (1361_1364delGTCT) resulted in a frameshift and premature protein truncation in the SSD. The other was a duplication mutation (3124_3129dupGTGTGC), which introduced 2 extra amino acid residues in the 8th transmembrane domain. The third one was a missense mutation (3913G>T), which caused exchange of an acidic amino acid (Asp) for a neutral polar amino acid (Tyr) near the C terminus of the PTCH protein. To characterize further the 4 novel mutations identified in the present study, we tested 100 unrelated control DNA samples by PCR-SSCP analysis and found that the abnormal SSCP migration bands seen in the 4 novel mutant samples were absent from the control DNAs (see APPENDIX). Therefore, these newly identified mutations are unlikely to be rare polymorphisms. Thus, analysis of our data provides further evidence that defects of PTCH are involved in the formation of syndromic as well as non-syndromic keratocysts, although further studies are now required to identify how these mutations may impair PTCH function.
Eight polymorphisms, previously reported in North American (Xie et al., 1997), European (Richards et al., 1997; Bodak et al., 1999; Boutet et al., 2003), and Japanese (Fujii et al., 2003) populations, were also identified in 11 of the 12 patients in the present series. Some of these polymorphic variants (i.e., 1686C>T, 2199A>G, 3944T>C, IVS10-51G>C, IVS10-8T>C) occurred with a high frequency, and eight patients had 2 or more polymorphisms. A recent study has reported that certain haplotypes of PTCH polymorphisms could mediate susceptibility to basal cell carcinomas (Strange et al., 2004). Further studies are needed to define such an association between susceptibility to odontogenic keratocyst formation and PTCH polymorphisms.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Received March 24, 2005; Last revision March 4, 2006; Accepted May 11, 2006
| REFERENCES |
|---|
|
|
|---|
Bodak N, Queille S, Avril MF, Bouadjar B, Drougard C, Sarasin A, et al. (1999). High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc Natl Acad Sci USA 96:51175122.
Boutet N, Bignon YJ, Drouin-Garraud V, Sarda P, Longy M, Lacombe D, et al. (2003). Spectrum of PTCH1 mutations in French patients with Gorlin syndrome. J Invest Dermatol 121:478481.[ISI][Medline]
Browne RM (1971). The odontogenic keratocyst. Histological features and their correlation with clinical behaviour. Br Dent J 131:249259.[ISI][Medline]
Chidambaram A, Goldstein AM, Gailani MR, Gerrard B, Bal SJ, DiGiovanna JJ, et al. (1996). Mutations in the human homologue of the Drosophila patched gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients. Cancer Res 56:45994601.
Cobourne MT, Miletich I, Sharpe PT (2004). Restriction of sonic hedgehog signalling during early tooth development. Development 131:28752885.
Dassule HR, Lewis P, Bei M, Maas R, McMahon AP (2000). Sonic hedgehog regulates growth and morphogenesis of the tooth. Development 127:47754785.[Abstract]
den Dunnen JT, Antonarakis SE (2000). Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:712.[ISI][Medline]
Evans DG, Farndon PA (2004). Nevoid basal cell carcinoma syndrome. Gene Review, at www.genetests.org.
Fujii K, Kohno Y, Sugita K, Nakamura M, Moroi Y, Urabe K, et al. (2003). Mutations in the human homologue of Drosophila patched in Japanese nevoid basal cell carcinoma syndrome patients. Hum Mutat 21:451452.[Medline]
Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. (1996). The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14:7881.[ISI][Medline]
Gorlin RJ (1987). Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 66:98113.[Medline]
Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, et al. (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841851.[ISI][Medline]
Hardcastle Z, Mo R, Hui CC, Sharpe PT (1998). The Shh signaling pathway in tooth development: defects in Gli2 and Gli3 mutants. Development 125:28032811.[Abstract]
Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272:16681671.[Abstract]
Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. (1997). Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69:299308.[ISI][Medline]
Lench NJ, Telford EA, High AS, Markham AF, Wicking C, Wainwright BJ (1997). Characterisation of human patched germ line mutations in naevoid basal cell carcinoma syndrome. Hum Genet 100:497502.[ISI][Medline]
Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE (1996). A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 12:8587.[ISI][Medline]
Li TJ, Browne RM, Matthews JB (1994). Quantification of PCNA+ cells within odontogenic jaw cyst epithelium. J Oral Pathol Med 23:184189.[ISI][Medline]
Lo Muzio L, Nocini PF, Savoia A, Consolo U, Procaccini M, Zelante L, et al (1999a). Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet 55:3440.[ISI][Medline]
Lo Muzio L, Nocini P, Bucci P, Pannone G, Consolo U, Procaccini M (1999b). Early diagnosis of nevoid basal cell carcinoma syndrome. J Am Dent Assoc 130:669674.
Ohki K, Kumamoto H, Ichinohasama R, Sato T, Takahashi N, Ooya K (2004). PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts. Int J Oral Maxillofac Surg 33:584592.[ISI][Medline]
Richards FM, Goudie DR, Cooper WN, Jene Q, Barroso I, Wicking C, et al. (1997). Mapping the multiple self-healing squamous epithelioma (MSSE) gene and investigation of xeroderma pigmentosum group A (XPA) and PATCHED (PTCH) as candidate genes. Hum Genet 101:317322.[ISI][Medline]
Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, et al. (1996). The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 384:129134.[Medline]
Strange RC, El-Genidy N, Ramachandran S, Lovatt TJ, Fryer AA, Smith AG, et al. (2004). Susceptibility to basal cell carcinoma: associations with PTCH polymorphisms. Ann Hum Genet 68(Pt 6):536545.[ISI][Medline]
Strutt H, Thomas C, Nakano Y, Stark D, Neave B, Taylor AM, et al. (2001). Mutations in the sterol-sensing domain of Patched suggest a role for vesicular trafficking in Smoothened regulation. Curr Biol 11:608613.[ISI][Medline]
Vorechovsky I, Unden AB, Sandstedt B, Toftgard R, Stahle-Backdahl M (1997). Trichoepitheliomas contain somatic mutations in the overexpressed PTCH gene: support for a gatekeeper mechanism in skin tumorigenesis. Cancer Res 57:46774681.
Xie J, Johnson RL, Zhang X, Bare JW, Waldman FM, Cogen PH, et al. (1997). Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 57:23692372.
This article has been cited by other articles:
![]() |
L.-S. Sun, X.-F. Li, and T.-J. Li PTCH1 and SMO Gene Alterations in Keratocystic Odontogenic Tumors J. Dent. Res., June 1, 2008; 87(6): 575 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z Fan, J Li, J Du, H Zhang, Y Shen, C-Y Wang, and S Wang A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family J. Med. Genet., May 1, 2008; 45(5): 303 - 308. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® |
| Journal of Dental Research ® | Critical Reviews (1990-2004) |